vs
Side-by-side financial comparison of FEDERAL AGRICULTURAL MORTGAGE CORP (AGM) and Amphastar Pharmaceuticals, Inc. (AMPH). Click either name above to swap in a different company.
Amphastar Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($183.1M vs $107.5M, roughly 1.7× FEDERAL AGRICULTURAL MORTGAGE CORP). On growth, FEDERAL AGRICULTURAL MORTGAGE CORP posted the faster year-over-year revenue change (6.1% vs -1.8%). Over the past eight quarters, FEDERAL AGRICULTURAL MORTGAGE CORP's revenue compounded faster (7.1% CAGR vs 3.2%).
The Federal Agricultural Mortgage Corporation, also known as Farmer Mac, is a stockholder-owned, federally chartered corporation established by the U.S. Congress in 1988 under the Agricultural Credit Act of 1987. It was created to establish a secondary market for agricultural real estate and housing mortgage loans, to increase liquidity and the availability of long-term, stable credit for farmers, ranchers, and rural communities.
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
AGM vs AMPH — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $107.5M | $183.1M |
| Net Profit | — | $24.4M |
| Gross Margin | — | 46.8% |
| Operating Margin | 56.3% | 19.4% |
| Net Margin | — | 13.3% |
| Revenue YoY | 6.1% | -1.8% |
| Net Profit YoY | — | -35.7% |
| EPS (diluted) | $3.69 | $0.51 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $107.5M | $183.1M | ||
| Q3 25 | $104.0M | $191.8M | ||
| Q2 25 | $102.6M | $174.4M | ||
| Q1 25 | $94.3M | $170.5M | ||
| Q4 24 | $101.3M | $186.5M | ||
| Q3 24 | $90.3M | $191.2M | ||
| Q2 24 | $89.9M | $182.4M | ||
| Q1 24 | $93.7M | $171.8M |
| Q4 25 | — | $24.4M | ||
| Q3 25 | $55.0M | $17.4M | ||
| Q2 25 | $54.8M | $31.0M | ||
| Q1 25 | $49.7M | $25.3M | ||
| Q4 24 | $56.5M | $38.0M | ||
| Q3 24 | $49.8M | $40.4M | ||
| Q2 24 | $47.1M | $37.9M | ||
| Q1 24 | $53.7M | $43.2M |
| Q4 25 | — | 46.8% | ||
| Q3 25 | — | 51.4% | ||
| Q2 25 | — | 49.6% | ||
| Q1 25 | — | 50.0% | ||
| Q4 24 | — | 46.5% | ||
| Q3 24 | — | 53.3% | ||
| Q2 24 | — | 52.2% | ||
| Q1 24 | — | 52.4% |
| Q4 25 | 56.3% | 19.4% | ||
| Q3 25 | 64.1% | 13.2% | ||
| Q2 25 | 63.8% | 24.2% | ||
| Q1 25 | 66.9% | 21.9% | ||
| Q4 24 | 67.5% | 24.2% | ||
| Q3 24 | 69.0% | 29.8% | ||
| Q2 24 | 65.9% | 30.3% | ||
| Q1 24 | 72.8% | 27.9% |
| Q4 25 | — | 13.3% | ||
| Q3 25 | 52.9% | 9.0% | ||
| Q2 25 | 53.4% | 17.8% | ||
| Q1 25 | 52.6% | 14.8% | ||
| Q4 24 | 55.8% | 20.4% | ||
| Q3 24 | 55.2% | 21.1% | ||
| Q2 24 | 52.4% | 20.8% | ||
| Q1 24 | 57.4% | 25.1% |
| Q4 25 | $3.69 | $0.51 | ||
| Q3 25 | $4.44 | $0.37 | ||
| Q2 25 | $4.48 | $0.64 | ||
| Q1 25 | $4.01 | $0.51 | ||
| Q4 24 | $4.62 | $0.74 | ||
| Q3 24 | $3.86 | $0.78 | ||
| Q2 24 | $3.68 | $0.73 | ||
| Q1 24 | $4.28 | $0.81 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $282.8M |
| Total DebtLower is stronger | $30.8B | $608.7M |
| Stockholders' EquityBook value | $1.7B | $788.8M |
| Total Assets | $35.4B | $1.6B |
| Debt / EquityLower = less leverage | 17.93× | 0.77× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $282.8M | ||
| Q3 25 | — | $276.2M | ||
| Q2 25 | — | $231.8M | ||
| Q1 25 | — | $236.9M | ||
| Q4 24 | — | $221.6M | ||
| Q3 24 | $842.1M | $250.5M | ||
| Q2 24 | $923.0M | $217.8M | ||
| Q1 24 | $745.1M | $289.6M |
| Q4 25 | $30.8B | $608.7M | ||
| Q3 25 | $29.2B | $608.6M | ||
| Q2 25 | $28.9B | $607.7M | ||
| Q1 25 | $28.0B | $603.9M | ||
| Q4 24 | $27.5B | $601.6M | ||
| Q3 24 | $27.2B | $596.4M | ||
| Q2 24 | $26.8B | $586.9M | ||
| Q1 24 | $26.8B | $594.0M |
| Q4 25 | $1.7B | $788.8M | ||
| Q3 25 | $1.7B | $776.7M | ||
| Q2 25 | $1.5B | $757.5M | ||
| Q1 25 | $1.5B | $751.3M | ||
| Q4 24 | $1.5B | $732.3M | ||
| Q3 24 | $1.5B | $727.7M | ||
| Q2 24 | $1.5B | $713.3M | ||
| Q1 24 | $1.5B | $672.4M |
| Q4 25 | $35.4B | $1.6B | ||
| Q3 25 | $33.4B | $1.7B | ||
| Q2 25 | $33.0B | $1.6B | ||
| Q1 25 | $31.8B | $1.6B | ||
| Q4 24 | $31.3B | $1.6B | ||
| Q3 24 | $30.6B | $1.5B | ||
| Q2 24 | $30.2B | $1.5B | ||
| Q1 24 | $29.8B | $1.6B |
| Q4 25 | 17.93× | 0.77× | ||
| Q3 25 | 17.31× | 0.78× | ||
| Q2 25 | 18.70× | 0.80× | ||
| Q1 25 | 18.39× | 0.80× | ||
| Q4 24 | 18.48× | 0.82× | ||
| Q3 24 | 18.60× | 0.82× | ||
| Q2 24 | 17.87× | 0.82× | ||
| Q1 24 | 18.11× | 0.88× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $80.1M | $32.9M |
| Free Cash FlowOCF − Capex | — | $24.6M |
| FCF MarginFCF / Revenue | — | 13.4% |
| Capex IntensityCapex / Revenue | 0.0% | 4.5% |
| Cash ConversionOCF / Net Profit | — | 1.35× |
| TTM Free Cash FlowTrailing 4 quarters | — | $121.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $80.1M | $32.9M | ||
| Q3 25 | $74.2M | $52.6M | ||
| Q2 25 | $-47.7M | $35.6M | ||
| Q1 25 | $-49.8M | $35.1M | ||
| Q4 24 | $612.6M | $29.0M | ||
| Q3 24 | $-44.4M | $60.0M | ||
| Q2 24 | $56.1M | $69.1M | ||
| Q1 24 | $233.3M | $55.3M |
| Q4 25 | — | $24.6M | ||
| Q3 25 | — | $47.2M | ||
| Q2 25 | — | $25.0M | ||
| Q1 25 | — | $24.4M | ||
| Q4 24 | $607.4M | $16.6M | ||
| Q3 24 | $-44.4M | $46.2M | ||
| Q2 24 | $52.6M | $63.1M | ||
| Q1 24 | $231.7M | $46.5M |
| Q4 25 | — | 13.4% | ||
| Q3 25 | — | 24.6% | ||
| Q2 25 | — | 14.3% | ||
| Q1 25 | — | 14.3% | ||
| Q4 24 | 599.8% | 8.9% | ||
| Q3 24 | -49.2% | 24.1% | ||
| Q2 24 | 58.5% | 34.6% | ||
| Q1 24 | 247.3% | 27.1% |
| Q4 25 | 0.0% | 4.5% | ||
| Q3 25 | 0.0% | 2.8% | ||
| Q2 25 | 0.0% | 6.1% | ||
| Q1 25 | 0.0% | 6.3% | ||
| Q4 24 | 5.2% | 6.7% | ||
| Q3 24 | 0.1% | 7.2% | ||
| Q2 24 | 4.0% | 3.3% | ||
| Q1 24 | 1.7% | 5.1% |
| Q4 25 | — | 1.35× | ||
| Q3 25 | 1.35× | 3.03× | ||
| Q2 25 | -0.87× | 1.15× | ||
| Q1 25 | -1.00× | 1.39× | ||
| Q4 24 | 10.84× | 0.76× | ||
| Q3 24 | -0.89× | 1.48× | ||
| Q2 24 | 1.19× | 1.82× | ||
| Q1 24 | 4.34× | 1.28× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AGM
Segment breakdown not available.
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
